- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Gerd Munzert
Clinical Oncologist, Boehringer Ingelheim, Biberach, Germany
Personalised medicine is, of course, the way we would like to go, not only just in non-small cell lung cancer but also in many other solid tumour indications. I think the availability of markers that really define the patients that are having the most benefit is really the limiting factor here. I think everybody is eager to test for biomarkers in all sorts of trials. And we are trying to identify other biomarkers in non-small cell lung cancer but also in other indications. But I think we’re lucky to have the EGFR mutations but as a discriminator but this is not the case in most solid tumours. But I think this is changing very rapidly so hopefully we will have the option for personalised therapies in also other indications.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
